Here we report the preliminary safety and efficacy results of LBL-007 (an anti-LAG-3 antibody) in combination with toripalimab (an anti-PD-1 antibody) in patients with advanced malignant tumors.Methods: Patients with advanced malignant tumors, including but not limited to nasopharyngeal carcinoma...
SHANGHAI,June 30, 2023/PRNewswire/ -- Chime Biologics, a leading CDMO that enables its partners' success in biologics, announced that it has established 3-way strategic cooperation with Leads Biolabs and BeiGene to accelerate LBL-007 mAb development and manufacturing for speedy clinical advancement...
A phase 2 study evaluating WU-CART-007, a first-in-class, investigational, anti-CD7 chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adult and pediatric patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukem...
Ghobadi A, Aldoss I, Maude SL, et al. WU-CART-007 (WT-7), an allogeneic CAR T-cell targeting CD7 in relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL): phase 2 results. Blood. 2024;144(suppl 1):3450. doi:10.1182/blood-2024-202005Newsletter Stay u...
results to date rely on the e and µ channels. Therefore, in what follows, we will use to refer to e or µ, unless noted otherwise. The initial and final-state quarks can radiate gluons that can be detected as additional jets. The number of jets reconstructed ...
Finding results verified the successful heparinization of the BPSs by the Layer-by-Layer self-assembly technique. The heparinized bovine pericardial scaffolds could be valuable candidate material in the cardiovascular field. 展开 关键词: Extracellular matrix Scaffold Decellularization Heparin Layer-by-...
These results imply that our method of device optimization offers a special set of abilities to PSC research that may be used in a real-world device fabrication process in the lab, saving the researchers money and time. Device modeling and device structure Device modeling SCAPS-1D has been ...
Results: Between November 30, 2021, and December 1, 2023, 80 patients were enrolled, including 30 (37.5%) with NPC and 50 (62.5%) with other tumors. Median follow-up was 26.0 months. In Phase Ib, LBL-007 was administered at 200 mg to four patients and 400 mg to six patients, with...
Here we report the safety and efficacy of LBL-007 (anti-LAG-3) in combination with tislelizumab (anti-PD1) with or without chemotherapy in advanced solid tumors (Phase Ⅰb) and previously untreated patients with advanced nasopharyngeal carcinoma (NPC) (Phase II).Methods:In phase Ⅰb, ...
Here we report the preliminary safety and efficacy of LBL-007 in combination with Toripalimab (an anti-PD-1 antibody has approved for treatment of melanoma in China) in patients (pts) with unresectable or metastatic melanoma.Methods:Pts with unresectable or metastatic melanoma with or without ...